Biocon Biologics Limited (BBL) is a fully integrated, innovation-led company committed to transforming patients’ lives by enabling affordable access to high-quality biosimilars for patients and healthcare systems, either directly or through a network of partners and distributors, in over 100+ countries.
BBL has demonstrated success with multiple successful biosimilar approvals in U.S., Europe and several other advanced and developing countries. It has eight  commercialized products in global markets. It is the first company in the world to obtain U.S. Food and Drug Administration (FDA) approval for an interchangeable biosimilar, received for its Insulin Glargine.
The company has a broad pipeline of 20 biosimilar molecules spanning insulins, monoclonal antibodies and conjugated recombinant proteins with a strong focus on diabetology, oncology and immunology, targeting an over USD 70 billion addressable market by FY27 .
Through its recent strategic alliance with the Serum Institute Life Sciences (SILS), BBL will be able to diversify its business beyond biosimilars and have access to a portfolio of vaccines targeting several communicable diseases.
Biocon Biologics has invested over USD 1 billion to date in R&D and global scale manufacturing and has end-to-end capabilities for producing drug substance, drug product and delivery devices across multiple sites in India and Malaysia.
It is also among the Top 15 global biopharma players in terms of installed capacity and has a strong track record of compliance and quality with GMP certifications and approvals from key regulators such as U.S. FDA, European Medicines Agency, Therapeutic Goods Administration (Australia), Health Canada, PMDA (Japan) and many others.
Biocon Biologics is committed to Environmental, Social, and Governance initiatives with clear annual targets for key metrics such as the use of renewable energy, expanding access to biosimilars in low- and middle-income countries (LMICs) and gender diversity.
People are core to BBL’s mission and success. It remains committed to employee-centric policies, building a diverse and inclusive workplace culture, and investing in talent through various initiatives and programs.
Apart from the parent company, Biocon Biologics’ investors include Goldman Sachs, True North, Tata Capital, Abu Dhabi Development Holding Company (ADQ), Serum (subject to closing of the previously announced merger with Covidshield Technologies, a wholly owned subsidiary of Serum) and Viatris.